Sign In
Buy LYEL
$12.57
-2.32 (-15.58%)
At Close: Jun 03, 2026
SOUTH SAN FRANCISCO, Calif., March 09, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor
Lyell Immunopharma, Inc. (LYEL) Presents at TD Cowen 46th Annual Health Care Conference Transcript
04:55pm, Friday, 06'th Mar 2026
Lyell Immunopharma, Inc. (LYEL) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Lyell Immunopharma Announces Participation in March Investor Conferences
08:00am, Monday, 23'rd Feb 2026
SOUTH SAN FRANCISCO, Calif., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation chimeric antigen receptor (CAR)
SOUTH SAN FRANCISCO, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation chimeric antigen receptor (CAR)
Lyell Immunopharma (NASDAQ:LYEL) Stock Price Down 4.6% – Here’s What Happened
05:46am, Sunday, 04'th Jan 2026
Shares of Lyell Immunopharma, Inc. (NASDAQ: LYEL - Get Free Report) were down 4.6% during mid-day trading on Friday. The company traded as low as $29.71 and last traded at $29.35. Approximately 12,364
Lyell Immunopharma (NASDAQ:LYEL) Trading Down 6.7% – Should You Sell?
02:36am, Sunday, 28'th Dec 2025
Lyell Immunopharma, Inc. (NASDAQ: LYEL - Get Free Report) shares traded down 6.7% during trading on Friday. The stock traded as low as $36.00 and last traded at $36.02. 25,191 shares changed hands dur
The Zacks Analyst Blog Mineralys, Lyell, Insmed and Nektar
03:35am, Friday, 26'th Dec 2025
Mineralys Therapeutics leads a biotech surge, with four drug stocks up over 50% in 2025 and catalysts lining up for more upside in 2026.
Critical Review: Lipocine (NASDAQ:LPCN) & Lyell Immunopharma (NASDAQ:LYEL)
02:18am, Friday, 26'th Dec 2025
Lyell Immunopharma (NASDAQ: LYEL - Get Free Report) and Lipocine (NASDAQ: LPCN - Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two busi
4 Drug, Biotech Stocks Rising More Than 50% in 2025 With Room to Grow
11:56am, Wednesday, 24'th Dec 2025
MLYS, LYEL, NKTR and INSM rise more than 50% in 2025 as clinical wins, FDA approvals and M&A deals revive sector momentum heading into 2026.
Lyell Immunopharma: LYL314 Drives Momentum Amid Strong ASH Data
08:30am, Wednesday, 24'th Dec 2025
Lyell Immunopharma (LYEL) has surged 191% YTD, driven by strong momentum and promising CAR T-cell therapy pipeline candidates LYL314 and LYL273. LYL314 achieved a 93% overall response and 76% complete
Precision's Payoff: Targeted Therapies Drive $131B Solid Tumor Market Surge
06:00am, Wednesday, 24'th Dec 2025
VANCOUVER, British Columbia, Dec. 24, 2025 (GLOBE NEWSWIRE) -- Equity Insider News Commentary - The U. S. oncology market is projected to surge from $81 billion in 2025 to $212 billion by 2034[1], dri
SOUTH SAN FRANCISCO, Calif., Dec. 07, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation chimeric antigen receptor (CAR)
Lyell Immunopharma (NASDAQ:LYEL) Sets New 12-Month High – Here’s What Happened
02:20am, Sunday, 07'th Dec 2025
Lyell Immunopharma, Inc. (NASDAQ: LYEL - Get Free Report)'s share price reached a new 52-week high on Friday. The company traded as high as $25.59 and last traded at $25.46, with a volume of 93527 sha
Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2025
04:05pm, Wednesday, 12'th Nov 2025
Acquired exclusive global rights to LYL273, a novel GCC-targeted CAR T-cell product candidate that has demonstrated a 67% overall response rate, an 83% disease control rate and a manageable safety pro
LYL273 has demonstrated a 67% overall response rate, an 83% disease control rate, and a manageable safety profile at the highest dose level studied to date in patients with refractory metastatic color
